Targeted ovarian cancer therapy not cost-effective, study suggests
Monday, March 7, 2011 - 22:30
in Health & Medicine
An analysis conducted by cancer researchers has found that adding the targeted therapy bevacizumab to the treatment of patients with advanced ovarian cancer is not cost effective.